Terns reports Q3 net loss $24.6M; TERN-701 CML data 75% MMR at 24 weeks; halts TERN-601 GLP-1 obesity program

Terns Pharmaceuticals, Inc.

2025-Q3 EPS reported -$0.79

TERN-701 Phase 1 CARDINAL trial: overall MMR rate 75% by 24 weeks; 69% in patients with lack of efficacy to prior TKI.
TERN-601 Phase 2 obesity study: 4.6% placebo-adjusted weight loss, 12% discontinuation due to AEs, reversible liver enzyme elevations; development stopped.
Cash, cash equivalents and marketable securities of $295.6M as of Sep 30, 2025, expected to fund operations into 2028.
Q3 2025 net loss $24.6M vs $21.9M in Q3 2024; R&D expense rose to $19.9M from $15.2M.
Seeking strategic partners for TERN-501 (THR-β agonist) and TERN-801 (GIPR antagonist) metabolic programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.